Roche Pharma (Schweiz) AG - Madopar 62.5, Kapseln | | 38096 | | 01 | | Madopar 62.5 | | Kapseln | | N04BA02 | | Levodopa and Decarboxylase Inhibitor | | 23.06.1978 | | |
| Composition | levodopum 50.00 mg, benserazidum 12.50 mg ut benserazidi hydrochloridum, mannitolum, cellulosum microcristallinum, talcum, povidonum K 90, magnesii stearas, Kapselhülle: E 172 (nigrum), E 171, E 132, gelatina, Drucktinte: lacca, propylenglycolum, ammoniae solutio 28 per centum, kalii hydroxidum, E 172 (nigrum), pro capsula. | Packungsbestandteile | | Capsules | | | Active Agent | Dose |
---|
Benserazide | 12.5 mg | Levodopa | 50 mg |
| BAG: Active Agent | Dose |
---|
Benserazide | 12.5 mg | Levodopa | 50 mg |
| | Inactive agents | Dose | additional_information |
---|
(Nigrum) | | | Ammoniae Solutio | 28 | | Cellulosum Microcristallinum | | | E 132 | | color. | E 171 | | color. | E 172 | | color. | Gelatina | | | Kalii Hydroxidum | | | Lacca | | Drucktinte | Magnesii Stearas | | | Mannitol | | | Per Centum | | | Povidonum K | 90 | | Pro Capsula | | | Propylenglycol | | | Talcum | | |
| |
| Teilbarkeit | | | -- | | | | Ja (sofort anwenden!) | | | | Nein | | | | Ja | | | | Die Kapseln dürfen erst unmittelbar vor der Verabreichung geöffnet werden, weil der Wirkstoff sehr instabil ist. [2] | | | | |
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
---|
095 | 100 Capsule(s) | 8.48 | 18.30 | B | SL | Yes |
|
|